drugset

drugset / Trial / NCT03913741

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

NCT03913741 ↗

Phase 1/2 Completed 23 enrolled Genmab Seagen Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies

Timeline

Start: 2019-02-27
Primary completion: 2020-08-14
Completion: 2021-10-30

Publications

Results Yonemori K, Kuboki Y, Hasegawa K, Iwata T, Kato H, Takehara K, Hirashima Y, Kato H, Passey C, Buchbjerg JK, Harris JR, Andreassen CM, Nicacio L, Soumaoro I, Fujiwara K. Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. Cancer Sci. 2022 Aug;113(8):2788-2797. doi: 10.1111/cas.15443. Epub 2022 Jun 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tisotumab Vedotin	Other / unclassified	1.5 mg/kg	Intravenous
Subject	Tisotumab Vedotin	Other / unclassified	2 mg/kg	Intravenous

Indications